We have provided evidence that STAT1 attenuates the tumorigenicity of ESCC by inhibiting the STAT3 and NF-κB signaling pathway, and therefore that activation of STAT1 may be a useful approach to treat ESCC. This evidence concerns the gene NFKB1 and esophageal squamous cell carcinoma.